師資內容

DSC01607-1

研究室：N844實驗室

電話：073121101 ext 2684

E-mail:yeloch@kmu.edu.tw

 

學歷：

  1. 東吳大學化學系理學士 (1987)
  2. 高雄醫學大學藥學研究所碩士 (1989)
  3. 中山大學化學研究所博士 (1999)

經歷：

  1. 現任高雄醫學大學醫藥暨應用化學系教授(2006.1-)
  2. 高雄醫學大學醫藥暨應用化學系副教授 (2002.8-2005.12)
  3. 高雄醫學大學醫藥暨應用化學系助理教授 (1998.8-2002.7)
  4. 高雄醫學大學醫藥暨應用化學系講師 (1991.8 – 1998.7)

開授科目：

有機化學(生技二)，醫藥品合成化學(一)，有機光譜特論(碩一)，醫藥品合成化學特論(碩一)

研究興趣：

設計合成新型雜環衍生物以探討其物性與化性，並研究其開發成為抗癌、抗菌或抗病毒的藥物

近期發表論文：

  1. Liu FC, Yu HP, Chen PJ, Yang HW, Chang SH, Tzeng CC, Cheng WJ, Chen YR, Chen YL,* Hwang TL* “A novel NOX2 inhibitor attenuates human neutrophil oxidative stress and ameliorates inflammatory arthritis in mice” Redox Biology, 2019, 26, 101273. (SCI, IF2018 = 7.793; 28/298, BIOCHEMISTRY & MOLECULAR BIOLOGY)
  2. Yang CY, Hung YL, Tang KW, Wang SC, Tseng CH, Tzeng CC, Liu PL, Li CY,* Chen YL* “Discovery of 2-Substituted 3-Arylquinoline Derivatives as Potential Anti-Inflammatory Agents Through Inhibition of LPS-Induced Inflammatory Responses in Macrophages” Molecules, 2019, 24(6), 1162/1-1162/19. (SCI, IF2018 = 3.060; 68/172, CHEMISTRY, MULTIDISCIPLINARY)
  3. Cheng KW, Tseng CH, Tzeng CC, Leu YL, Cheng TC, Wang JY, Chang JM, Lu YC, Cheng CM, Chen IJ, Cheng YA, Chen YL,* Cheng TL* “Pharmacological inhibition of bacterial β-​glucuronidase prevents irinotecan-​induced diarrhea without impairing its antitumor efficacy in vivo” Pharmacological Research, 2019, 139, 41-49. (SCI, IF2018 = 5.574; 18/267,  PHARMACOLOGY & PHARMACY)
  4. Chien CM, Yang JC, Wu PH, Wu CY, Chen GY, Wu YC, Chou CK, Yseng CH, Chen YL,* Wang LF,* Chiu CC* “Phytochemical Naphtho[1,2-b] furan-4,5-dione Induced Topoisomerase II-mediated DNA Damage Response in Human Non-small-Cell Lung Cancer” Phytomedicine 2019,54, 109-119. (SCI, IF2018 = 4.180; 1/27,  INTEGRATIVE & COMPLEMENTARY MEDICINE)
  1. Miller DR, Tzeng CC, Farmer T, Keller ET, Caplan S, Chen YS, Chen YL,* Lin MF* “Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer” Cancer Lett. 2018, 436, 96-108. (SCI, IF2017 = 6.491; 29/223, ONCOLOGY)
  1. Cheng KW, Tseng CH, Yang CN, Tzeng CC, Cheng TC, Leu YL, Chuang YC, Wang JY, Lu YC, Chen YL,* Cheng TL* “Specific Inhibition of Bacterial β-​Glucuronidase by Pyrazolo[4,​3-​c]​quinoline Derivatives via a pH-​Dependent Manner To Suppress Chemotherapy-​Induced Intestinal Toxicity” Med. Chem. 2017, 60, 9222-9238. (SCI, IF2016 = 6.259; 3/59, CHEMISTRY, MEDICINAL)
  2. Chang WT, Fong Y, Chuang SC, Chou CK, Chou HL, Yang CF, Tseng CH, Chen YL, Chiu, CC “9-​Bis[2-​(pyrrolidin-​1-​yl)​ethoxy]​-​6-​{4-​[2-​(pyrrolidin-​1-​yl)​ethoxy]​phenyl}​-​11H-​indeno[1,2-​c]​quinolin-​11-​one (BPIQ)​, A Quinoline Derivative Inhibits Human Hepatocellular Carcinoma Cells by Inducing ER Stress and Apoptosis” Anti-Cancer Agents Med. Chem. 2017, 17, 692-700. (SCI, IF2016 = 2.598; 30/60, CHEMISTRY, MEDICINAL)
  3. Fong Y, Wu CY, Chang KF, Chen BH, Chous WJ, Tseng CH, Chen YC, Wang HM, Chen YL*, Chiu CC* “Dual roles of extracellular signal-regulated kinase (ERK) in quinoline compound BPIQ-induced apoptosis and anti-migration of human non small cell lung cancer cells” Cancer Cell Int. 2017, 17-37. (SCI, IF2016 = 2.740; 121/217, ONCOLOGY)